All In Biotech

Drug Trial Radar · NCT06747923

SB17170 Phase 2 Trial in IPF Patients

A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jan 27, 2025

Primary completion

Jul 21, 2026

Study completion Jul 28, 2026

Sponsor

Lead sponsor
SPARK BiopharmaIndustry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

Conditions

  • IPF
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • SB17170Drug

    Taking SB17170 orally once a day

  • PlaceboDrug

    Taking Placebo orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in FVC (ml)Time frame: Week 12

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Myong Ji Hospital

    Goyang, South Korea

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, South Korea

  • Seoul Asan Hospital

    Seoul, South Korea

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.